MERCURYLABPharmaceuticals
Mercury Labs — Profit & Loss Statement
₹860.00
+0.00%
Mercury Labs Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.13 Cr | -0.02 Cr | — |
| Tax Rate For Calcs | 0.33 | 0.18 | 0.25 | 0.29 | — |
| Normalized EBITDA | 8.09 Cr | 10.12 Cr | 10.50 Cr | 7.72 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 3.14 Cr | 5.65 Cr | 5.58 Cr | 3.56 Cr | — |
| Reconciled Depreciation | 2.88 Cr | 2.82 Cr | 2.48 Cr | 2.45 Cr | — |
| Reconciled Cost Of Revenue | 28.92 Cr | 30.30 Cr | 30.61 Cr | 23.76 Cr | — |
| EBITDA | 8.09 Cr | 10.12 Cr | 9.98 Cr | 7.66 Cr | — |
| EBIT | 5.21 Cr | 7.30 Cr | 7.50 Cr | 5.20 Cr | — |
| Net Interest Income | -0.55 Cr | -0.38 Cr | -0.24 Cr | -0.36 Cr | — |
| Interest Expense | 0.55 Cr | 0.38 Cr | 0.06 Cr | 0.17 Cr | — |
| Normalized Income | 3.14 Cr | 5.65 Cr | 5.96 Cr | 3.61 Cr | — |
| Net Income From Continuing And Discontinued Operation | 3.14 Cr | 5.65 Cr | 5.58 Cr | 3.56 Cr | — |
| Total Expenses | 70.96 Cr | 69.34 Cr | 68.73 Cr | 53.15 Cr | — |
| Diluted NI Availto Com Stockholders | 3.14 Cr | 5.65 Cr | 5.58 Cr | 3.56 Cr | — |
| Net Income Common Stockholders | 3.14 Cr | 5.65 Cr | 5.58 Cr | 3.56 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 3.14 Cr | 5.65 Cr | 5.58 Cr | 3.56 Cr | — |
| Net Income Including Noncontrolling Interests | 3.14 Cr | 5.65 Cr | 5.58 Cr | 3.56 Cr | — |
| Net Income Continuous Operations | 3.14 Cr | 5.65 Cr | 5.58 Cr | 3.56 Cr | — |
| Tax Provision | 1.52 Cr | 1.27 Cr | 1.87 Cr | 1.47 Cr | — |
| Pretax Income | 4.66 Cr | 6.92 Cr | 7.44 Cr | 5.03 Cr | — |
| Other Non Operating Income Expenses | 1.07 Cr | 1.09 Cr | 0.36 Cr | 0.25 Cr | — |
| Net Non Operating Interest Income Expense | -0.55 Cr | -0.38 Cr | -0.24 Cr | -0.36 Cr | — |
| Interest Expense Non Operating | 0.55 Cr | 0.38 Cr | 0.06 Cr | 0.17 Cr | — |
| Operating Income | 4.14 Cr | 6.21 Cr | 6.60 Cr | 4.78 Cr | — |
| Operating Expense | 42.04 Cr | 39.04 Cr | 38.13 Cr | 29.38 Cr | — |
| Other Operating Expenses | 22.33 Cr | 21.72 Cr | 15.13 Cr | 10.59 Cr | — |
| Depreciation And Amortization In Income Statement | 2.88 Cr | 2.82 Cr | 2.48 Cr | 2.45 Cr | — |
| Depreciation Income Statement | 2.88 Cr | 2.82 Cr | 2.46 Cr | 2.45 Cr | — |
| Gross Profit | 46.19 Cr | 45.26 Cr | 44.73 Cr | 34.16 Cr | — |
| Cost Of Revenue | 28.92 Cr | 30.30 Cr | 30.61 Cr | 23.76 Cr | — |
| Total Revenue | 75.10 Cr | 75.56 Cr | 75.33 Cr | 57.92 Cr | — |
| Operating Revenue | 75.10 Cr | 75.56 Cr | 75.33 Cr | 57.92 Cr | — |
| Total Unusual Items | — | -1.38 Cr | -0.51 Cr | -0.07 Cr | -1.54 Cr |
| Total Unusual Items Excluding Goodwill | — | -1.38 Cr | -0.51 Cr | -0.07 Cr | -1.54 Cr |
| Interest Income | — | 0.12 Cr | 0.12 Cr | 0.09 Cr | 0.06 Cr |
| Rent Expense Supplemental | — | 0.07 Cr | 0.04 Cr | 0.10 Cr | 0.55 Cr |
| Diluted Average Shares | — | 0.12 Cr | 0.12 Cr | 0.12 Cr | 0.12 Cr |
| Basic Average Shares | — | 0.12 Cr | 0.12 Cr | 0.12 Cr | 0.12 Cr |
| Diluted EPS | — | 47.12 | 46.49 | 29.68 | 44.48 |
| Basic EPS | — | 47.12 | 46.49 | 29.68 | 44.48 |
| Special Income Charges | — | -1.38 Cr | -0.51 Cr | -0.07 Cr | -1.54 Cr |
| Other Special Charges | — | -0.07 Cr | 0.03 Cr | 0.05 Cr | 0.50 Cr |
| Write Off | — | 1.45 Cr | 0.48 Cr | 0.01 Cr | 1.05 Cr |
| Total Other Finance Cost | — | 0.32 Cr | 0.30 Cr | 0.28 Cr | 0.39 Cr |
| Interest Income Non Operating | — | 0.12 Cr | 0.12 Cr | 0.09 Cr | 0.06 Cr |
| Amortization | — | 0.02 Cr | 0.02 Cr | 0.03 Cr | 0.02 Cr |
| Research And Development | — | 0.02 Cr | 85000.00 | 0.02 Cr | 26000.00 |
| Selling General And Administration | — | 6.12 Cr | 6.22 Cr | 3.70 Cr | 4.88 Cr |
| Selling And Marketing Expense | — | 4.52 Cr | 5.08 Cr | 2.81 Cr | 3.76 Cr |
| General And Administrative Expense | — | 1.60 Cr | 1.13 Cr | 0.89 Cr | 1.12 Cr |
| Rent And Landing Fees | — | 0.07 Cr | 0.04 Cr | 0.10 Cr | 0.55 Cr |
| Net Income Discontinuous Operations | — | — | — | 0.00 | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Mercury Labs
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.